Cytosorbents (CTSO) Cash from Financing Activities (2010 - 2025)

Cytosorbents (CTSO) has 16 years of Cash from Financing Activities data on file, last reported at $2.5 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 1383.83% year-over-year to $2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $9.3 million (changed 0.24% YoY) and the FY2025 annual result came in at $9.3 million, changed 0.24% from the prior year.
• Cash from Financing Activities slipped to $2.5 million in Q4 2025, from $6.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $12.2 million in Q4 2023 to a low of -$571762.0 in Q1 2024.
• A 5-year average of $2.4 million and a median of $619020.5 in 2021 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities surged 6278.64% — and 2024, when it sank 183.56%.
• Tracing CTSO's Cash from Financing Activities over 5 years: stood at -$80924.0 in 2021, then surged by 6278.64% to $5.0 million in 2022, then soared by 144.21% to $12.2 million in 2023, then plunged by 98.63% to $167000.0 in 2024, then jumped by 1383.83% to $2.5 million in 2025.
• The last three Cash from Financing Activities figures came in at $2.5 million (Q4 2025), $6.8 million (Q1 2025), and $167000.0 (Q4 2024), per Business Quant data.